Business / Finance

RSS

Inoviem Scientific receives €545,000 from French public investment bank bpifrance

Inoviem Scientific, a Contract Research Biotech (CRB) company today announces that it has received additional funding of €545,000 ($611,000) from French public investment bank bpifrance. The company leverages two proprietary technologies to offer pharmaceutical players increased speed and enhanced safety at all stages of drug development; from drug discovery (the identification of secondary targets and detection of potential adverse effects, etc.) through to clinical trials (with patient stratification and identification of biomarkers, etc.).

12 May 2015

CPhI Istanbul 2015 opens as Turkey continues to dominate the MENA pharma region

Turkey is fast emerging as a new hub for pharma manufacturing. This year, CPhI Istanbul will welcome more than 200 exhibitors from 23 Countries and over 4,000 visitors..

12 May 2015

Perrigo announces acquisition of Patheon's Mexican operations for $34 million

Perrigo Company plc announced today that it has acquired the Mexican operations of Durham, North Carolina-based Patheon for $34 million in cash.

12 May 2015

Cardiome signs commercialization agreement with AOP for ESMOCARD products

Cardiome Pharma Corp. today announced that the company has entered a commercialization agreement with AOP Orphan Pharma to sell AOP's cardiovascular products, ESMOCARD and ESMOCARD LYO (esmolol hydrochloride) in Italy, France, Spain and Belgium.

12 May 2015

China Pharma revenue decreases 20% to $5.7 million in Q1 2015

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended March 31, 2015.

12 May 2015

GP out-of-hours reforms linked to more emergency admissions for children

A study published today in Annals of Family Medicine, funded by the National Institute for Health Research, found that the GP contract was associated with an eight per cent increase in short stay admissions for potentially avoidable chronic conditions...

12 May 2015

Going to the dentist just got a little less scary for U.S. children with autism

Going to the dentist might have just gotten a little less scary for the estimated 1 in 68 U.S. children with autism spectrum disorder as well as children with dental anxiety, thanks to new research from USC.

12 May 2015

JHL Biotech closes $45.6 million Series C round of financing

JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series C fundraising of $45.6 million, led by funds managed by a global renowned crossover fund with over US$1.6 trillion in AUM, with participation from existing investor Milestone Capital and new investors Sungent BioVenture and Liwick Investment Management.

12 May 2015

The Project Data Sphere® initiative achieves 1st year milestones

Cancer community broadly shares, integrates, and analyzes clinical trial data within a single research platform to advance innovation and improve lives...

11 May 2015

Debiotech agrees to acquire exclusive rights on iSense CGM technology for use with patch pumps

Debiotech of Switzerland and iSense CGM, Inc. of the US, announced today having entered into an Agreement under which Debiotech has the option to acquire the exclusive rights on the iSense CGM product and technology for use with patch pumps for diabetes therapy. Financial terms and conditions of the Agreement are not disclosed.

11 May 2015

Nevro Q1 revenue increases 45% to $9.7 million

Nevro Corp., a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today reported financial results for the three months ended March 31, 2015.

11 May 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015.

8 May 2015

GenVec reports net loss of $1.5 million for first quarter 2015

GenVec, Inc. today reported financial results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.4 million, compared with a net loss of $1.0 million, or $0.07 per share, on revenues of $2.1 million, for the same period in the prior year.

8 May 2015

Pain management webinar addresses fibromyalgia, "the invisible disease"

Topical BioMedics is hosting its free monthly pain management webinar on Tuesday, May 12th, focusing on the topic “What You need to Know about Fibromyalgia.” The webinar, which is free and open to the public, will be streamed live from 12pm to 1pm, then archived and accessible on demand 24/7...

7 May 2015

Cyclenium Pharma, Haplogen sign agreement to discover novel pharmaceutical candidates

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on its proprietary macrocyclic chemistry technology, and Haplogen GmbH, a biotechnology company developing anti-infective drugs, today announced the signing of a research agreement aimed at the discovery of novel pharmaceutical candidates in multiple disease areas.

7 May 2015

Unique real-time drug monitoring system

Titan Enterprises assisted CRISI in the early days of development of the unique flow sensor used in the BD Intelliport™, a medication management system for manual intravenous (IV) bolus injections...

From Titan Enterprises Ltd 7 May 2015

Egalet announces business highlights, financial results for first quarter 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today reported business highlights and financial results for the three months ended March 31, 2015.

7 May 2015

BD reports revenues of $2.051 billion for second fiscal quarter 2015

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for the second fiscal quarter ended March 31, 2015, representing a decrease of 1.0 percent from the prior-year period, or an increase of 4.9 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 7 May 2015

Wearable cognitive assessment devices a step closer as Cambridge Cognition file new patents

The combination of bio-behavioural measures and results from touch-screen cognitive tests would be used to build up a picture of a person’s mental function...

7 May 2015

Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of haemophilia, is expected to drive the associated therapeutics market. Recombinant therapies are likely to command a premium price and fuel growth in developed markets, while heightened access to treatment and larger patient volumes due to more funding for critical care are anticipated to contribute to demand in emerging markets.

7 May 2015